Repligen Corp at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (Virtual) Transcript
This is Paul Knight, the analyst at a KeyBanc on the life science industry covering Repligen. It's great to have with us today Jon Snodgres, the CFO; and Tony Hunt, CEO of Repligen. And I think that's it from Repligen, right, Tony?
Yes. Yes. We've got Sondra and Steven here as well, but Jon, myself will probably be doing most of talking.
Okay. I know you may have been on the investor (inaudible) a little while already this year, but if you want to make a few opening comments about the market, please do. And then we'll have some questions develop.
Yes. Maybe start, Paul, with where Repligen is coming out of 2022 and what we think are maybe things
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
